CONMED Corporation - Common Stock (CNMD)

Medical tech company CONMED (NYSE:CNMD) announced better-than-expected revenue in Q4 CY2025, with sales up 7.9% year on year to $373.2 million. On the other hand, the company’s full-year revenue guidance of $1.36 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $1.43 per share was 8% above analysts’ consensus estimates.

CONMED (CNMD) Q4 2025 Earnings Call Transcript

Medical tech company CONMED (NYSE:CNMD) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 7.9% year on year to $373.2 million. On the other hand, the company’s full-year revenue guidance of $1.36 billion at the midpoint came in 0.7% below analysts’ estimates. Its non-GAAP profit of $1.43 per share was 8% above analysts’ consensus estimates.

Medical tech company CONMED (NYSE:CNMD) will be announcing earnings results this Wednesday after market close. Here’s what you need to know.

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including CONMED (NYSE:CNMD) and its peers.

Over the past six months, CONMED’s stock price fell to $43.42. Shareholders have lost 13.3% of their capital, which is disappointing considering the S&P 500 has climbed by 11.1%. This may have investors wondering how to approach the situation.

What a brutal six months it’s been for CONMED. The stock has dropped 20.6% and now trades at $42.52, rattling many shareholders. This may have investors wondering how to approach the situation.

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Shares of medical tech company CONMED (NYSE:CNMD) jumped 3.3% in the afternoon session after positive sentiment in the medical device sector was buoyed by the highly successful initial public offering (IPO) of medical supply giant Medline (MDLN). 

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Shares of medical tech company CONMED (NYSE:CNMD) fell 6.2% in the morning session after the company announced its plan to exit its gastroenterology product lines as part of a broader portfolio adjustment. 

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 14.5% over the past six months while the S&P 500 was up 11.5%.

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

CONMED’s third quarter results were marked by steady revenue growth in both orthopedics and general surgery, supported by continued surgeon adoption of core products like BioBrace and the AirSeal platform. Management pointed to improvements in supply chain operations, especially within orthopedics, as a factor in supporting incremental sales growth. CEO Patrick Beyer credited “expanding clinical adoption and strong surgeon engagement” for BioBrace’s performance, while also highlighting operational progress in reducing back orders and improving service levels.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Medical tech company CONMED (NYSE:CNMD) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 6.7% year on year to $337.9 million. The company expects the full year’s revenue to be around $1.37 billion, close to analysts’ estimates. Its non-GAAP profit of $1.08 per share was 2.7% above analysts’ consensus estimates.

Medical tech company CONMED (NYSE:CNMD) announced better-than-expected revenue in Q3 CY2025, with sales up 6.7% year on year to $337.9 million. The company expects the full year’s revenue to be around $1.37 billion, close to analysts’ estimates. Its non-GAAP profit of $1.08 per share was 2.7% above analysts’ consensus estimates.

Medical tech company CONMED (NYSE:CNMD) will be reporting results this Wednesday after market close. Here’s what investors should know.

Let’s dig into the relative performance of CONMED (NYSE:CNMD) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - diversified earnings season.

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.